Core Insights - Orion Pharma has initiated a Phase 2 trial for ODM-212, an oral pan-TEAD inhibitor, targeting malignant pleural mesothelioma (MPM) and epithelioid hemangioendothelioma (EHE), both of which are rare and challenging cancers to treat [1][2][3] Trial Details - The TEADES trial is a multi-center, open-label study enrolling approximately 300 patients with MPM, EHE, or other solid tumors with Hippo pathway dysfunction, focusing on those who have progressed after standard treatments [2] - Primary endpoints include safety and tolerability, while secondary endpoints encompass Overall Response Rate, Progression Free Survival, and Overall Survival [2] Drug Mechanism and Development - ODM-212 functions as a pan-TEAD inhibitor, targeting the Hippo signaling pathway to prevent uncontrolled tumor growth and resistance to therapies by blocking TEAD transcription factors [4] - The first patient was treated in December 2025, marking a significant milestone in the clinical development of ODM-212 [1][3] Cancer Background - Malignant Pleural Mesothelioma (MPM) accounts for 80-90% of mesothelioma cases and is primarily linked to asbestos exposure, with current treatments being limited to chemotherapy and immunotherapy [5] - Epithelioid Hemangioendothelioma (EHE) is an ultra-rare vascular tumor with no standard treatment available, affecting less than one per million people [6] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a century of experience, focusing on developing, manufacturing, and marketing pharmaceuticals and active ingredients, particularly in oncology and pain management [8]

Group 1 - Orion Corporation has converted 71,498 A shares into B shares, with the conversion recorded in the Trade Register on November 27, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,770,319 A shares and 109,363,959 B shares [1] - The total number of votes for the company's shares after the conversion is 744,770,339 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2]

Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience in developing, manufacturing, and marketing human and veterinary pharmaceuticals as well as active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain as core therapy areas in its pharmaceutical R&D [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Share Conversion - A total of 49,164 A shares of Orion Corporation have been converted into B shares, with the conversion recorded in the Trade Register on 24 October 2025 [1] - Following the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,841,817 A shares and 109,292,461 B shares [1] - The total number of votes associated with the company's shares after the conversion is 746,128,801 [1]

Core Viewpoint - Orion Corporation is set to publish its Interim Report for January–September 2025 on 28 October 2025, with a webcast scheduled for the same day to discuss the report [1][2]. Group 1: Financial Reporting - The Interim Report will be released at approximately 12.00 noon EET on 28 October 2025 [1]. - A live webcast and conference call for analysts, investors, and media representatives will take place at 13.30 EET on the same day [2]. Group 2: Webcast Details - The live webcast link will be available on Orion's website, and a recording will be accessible later the same day [2]. - Participants can join the conference call by registering through a provided link, with access details shared post-registration [3]. Group 3: Company Background - Orion is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals [5]. - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [5].

Group 1 - Orion Corporation has converted 80,802 A shares into B shares, with the conversion recorded on September 19, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,890,981 A shares and 109,243,297 B shares [1] - The total number of votes for the company's shares after the conversion is 747,062,917 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has converted 337,000 A shares into B shares, with the conversion recorded on August 20, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 31,971,783 A shares and 109,162,495 B shares [1] - The total number of votes for the company's shares after the conversion is 748,598,155 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company reported net sales of EUR 1,542 million in 2024 and employs approximately 3,700 professionals globally [2] - Orion's core therapy areas in pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Financial Reporting Schedule - Orion Corporation will publish its Financial Statement Release for 2025 on Thursday, 12 February 2026 [1] - The Interim Reports and Half-Year Financial Report for 2026 will be published on the following dates: - Interim Report for January-March 2026: Thursday, 23 April 2026 - Half-Year Financial Report for January-June 2026: Friday, 17 July 2026 - Interim Report for January-September 2026: Wednesday, 28 October 2026 [1] Annual General Meeting - The Annual General Meeting is scheduled for Tuesday, 24 March 2026 [2] Company Overview - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on developing, manufacturing, and marketing human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - The company has a diverse portfolio that includes proprietary and generic medicines as well as consumer health products, with core therapy areas in oncology and pain [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - Orion's A and B shares are listed on Nasdaq Helsinki [2]

Group 1 - Orion Corporation has converted 141,959 A shares into B shares, with the conversion recorded on June 23, 2025 [1] - After the conversion, the total number of shares in Orion Corporation is 141,134,278, consisting of 32,308,783 A shares and 108,825,495 B shares [1] - The total number of votes for the company's shares after the conversion is 755,001,155 [1] Group 2 - Orion Corporation is a Nordic pharmaceutical company with over a hundred years of experience, focusing on human and veterinary pharmaceuticals and active pharmaceutical ingredients [2] - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain, with proprietary products developed for treating cancer, neurological diseases, and respiratory diseases [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member, Karen Lykke Sørensen, under the Market Abuse Regulation [1] - The transaction involved the receipt of a share-based incentive, with a volume of 415 shares at a unit price of 0 EUR [1] - In 2024, Orion's net sales amounted to EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] Group 2 - Orion Corporation operates as a Nordic pharmaceutical company, developing, manufacturing, and marketing both human and veterinary pharmaceuticals [2] - The company has a diverse portfolio that includes proprietary and generic medicines, as well as consumer health products, focusing on oncology and pain in its pharmaceutical R&D [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Kari Jussi Aho, specifically concerning share-based incentives [1] - The transaction occurred on April 30, 2025, involving 415 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation is a Nordic pharmaceutical company with a history of over a hundred years, focusing on human and veterinary pharmaceuticals, and has a diverse portfolio including proprietary and generic medicines [2] Group 2 - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]